Schematic image of NK cell-engaging nanodrones (NKeNDs).
CREDIT: UNIST
A groundbreaking study led by Professor Sebyung Kang and Professor Sung Ho Park in the Department of Biological Sciences at UNIST has unveiled a remarkable breakthrough in cancer treatment.
The research team has successfully developed unprecedented “NK cell-engaging nanodrones” capable of selectively targeting and eliminating cancer cells, offering a potential solution for intractable types of cancers.
The innate lymphoid cells known as natural killer (NK) cells play a vital role in the body’s immune response against cancer. Numerous efforts have been made to harness the power of NK cells to develop effective cancer therapies. Now, the research team has designed and fabricated exceptional NK cell-engaging nanodrones, referred to as NKeNDs, using AaLS protein cage nanoparticles.
These groundbreaking NKeNDs simultaneously display cancer-targeting ligands, such as HER2Afb or EGFRAfb, and NK cell-recruiting ligands, aCD16Nb, on the surface of the AaLS through the SpyCatcher/SpyTag protein ligation system. The dual ligand-displaying NKeNDs, named HER2 @NKeND and EGFR@NKeND, have demonstrated the ability to selectively bind to HER2-overexpressing SK-OV-3 cells and EGFR-overexpressing MDA-MB-468 cells, respectively, as well as human NK cells.
The physical engagement of human NK cells with the target cancer cells mediated by the NKeNDs activates the NK cells, enabling them to effectively eliminate the target cancer cells in vitro. Remarkably, in SK-OV-3 tumor-bearing mice, the administration of HER2 @NKeNDs along with human PBMCs facilitates the infiltration of activated human NK cells into the tumor sites. As a result, tumor growth is significantly suppressed without causing noticeable side effects.
This groundbreaking study showcases a novel approach to developing cancer-specific NK cell engagers by utilizing protein cage nanoparticles and recombinant cancer cell binders. It offers tremendous potential for the selective treatment of previously intractable types of cancers.
Professor Kang Se-byung expressed his excitement about the study, stating, “This research presents new possibilities for immune treatment through NK cell delivery nanodrones, overcoming challenges such as the movement and survival of NK cells. We aim to provide new opportunities for customized treatments that selectively address various types of cancer through further research, including cancer-specific immune cell induction.”
Original Article: Revolutionary nanodrones enable targeted cancer treatment
More from: Ulsan National Institute of Science and Technology
The Latest Updates from Bing News
Go deeper with Bing News on:
NK cell-engaging nanodrones
- Use of Allogeneic NK Cells for Cancer Immunotherapy
NK cells are components of the innate immune system. They can recognize targets without prior sensitization, making them ideal candidates to manipulate for therapeutic use against cancer.
- Use of Allogeneic NK Cells for Cancer Immunotherapy
Overview of current approaches to improve effectiveness of adoptive transfer of NK cells by manipulation of the NK cell product, the host and the target. Human NK cells are a subset of peripheral ...
- Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
SAR443579 is an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager from a joint ... multi-specific antibody formats engaging NK cells through the activating receptors NKp46 ...
- Developing a Protocol for Generating Genetically Modified NK Cells
Natural killer (NK) cells target infected and oncogenic cells, but are difficult to work with in vitro. Discover novel approaches to producing genetically modified NK cells for cell therapy. Natural ...
- Schematic image of NK cell-engaging nanodrones (NKeNDs). (IMAGE)
Figure 1. Schematic image of NK cell-engaging nanodrones (NKeNDs). The activation of human NK cells in the presence of both target cancer cells and corresponding NKeNDs or other nanodrone variants ...
Go deeper with Bing News on:
Targeted cancer treatment
- More Is Not Always Better: Outdated Drug Dose Strategy in Breast Cancer
Treatments included targeted, endocrine, and chemotherapy ... and 43.2% missed at least one cancer treatment. The most common side effects were fatigue, nausea, low blood counts, diarrhea, and ...
- Oncolytic Viruses: A Promising New Option in Cancer Treatment
As part of its Speaking Out video series, Targeted Oncology spoke with Howard D. Edington, MD, about the benefits of using oncolytic viruses in cancer treatment.
- Most BCG-Unresponsive Bladder Cancer Responds to TAR-200 Treatment
TAR-200 is a new treatment for high-risk bladder cancer that hasn't responded to other treatments. It is a targeted releasing system designed to deliver gemcitabine directly into the bladder. In a ...
- Researchers generate direct measurement of interaction between immune cells and cancer cells from a patient's biopsy
Researchers at Bar-Ilan University have unveiled a technology that promises to improve cancer treatment decisions based on a patient's biopsy. The pioneering biological research and development ...
- Targeted Therapy Provides Greatest OS Benefit if Started Within 1 Month of NSCLC Diagnosis
A new study suggests that starting a patient on preferred targeted therapy within 1 year of metastatic non-small cell lung cancer diagnosis can still improve overall survival, when compared to other ...